689
Abstract Views
482
PDF Download
Hematology

Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience: SS

Mehmet Bakırtaş Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence drbakirtas@hotmail.com
ORCID : http://orcid.org/0000-0003-3216-482X
,
Tuğçe Nur Yiğenoğlu Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence dr.nuryigenoglu@gmail.com
ORCID : http://orcid.org/0000-0001-9962-8882
,
Semih Başcı Ankara Oncology Training and Research Hospital, Turkey Correspondence dr.semihbasci@gmail.com
,
Bahar Uncu Ulu Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence baharuncu@gmail.com
ORCID : http://orcid.org/0000-0002-6230-9519
,
Nurgül Özcan Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence nersoyozcan@gmail.com
ORCID : http://orcid.org/0000-0001-8819-5153
,
Dicle Ä°skender Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence diclekoca@yahoo.com
ORCID : http://orcid.org/0000-0002-6062-6422
,
Mehmet Sinan Dal Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence dr.sinandal@gmail.com
ORCID : http://orcid.org/0000-0002-5994-2735
,
Merih Kızıl Çakar Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence merihkizil@yahoo.com
ORCID : http://orcid.org/0000-0003-0978-0923
,
Fevzi AltuntaÅŸ Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey, Turkey Correspondence venacavamedia@hotmail.com
ORCID : http://orcid.org/0000-0001-6872-3780
Pages 87-96
Browse this journal

Abstract

Acute leukaemia patients who relapse after the first allogeneic stem cell transplantation (Allo-SCT) have a poor prognosis. Participating in clinical trials is the best option for these patients. If patients cannot participate in clinical trials, as the treatment options are limited, the second allo-SCT constitutes the potential curative treatment option. The data of acute leukaemia patients who underwent second allo-SCT because of relapsed/refractory disease after the first allo-SCT at our centre between December 2009 and February 2019 were analyzed retrospectively. Three hundred nineteen acute leukaemia patients were performed allo-SCT at our centre. 20 of these 319 acute leukaemia patients relapsed after first allo-SCT and underwent second allo-SCT. 10 AML patients and 10 ALL patients were included in the study. After second allo-SCT overall survival (OS) was 26.1±10.8 weeks, and progression-free survival (PFS) was 19.9±8.6 weeks. If the patients cannot participate in clinical trials, second allo-SCT should be considered for patients with late (≥12 months) relapses after the first allo-SCT. If possible, haploidentical donors should be selected for second allo-SCT and patients should be in complete remission before the transplant.

There is no Figure or data content available for this article

References

1. Fey MF, Buske C, ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2013;24 Suppl 6:vi138-43. doi:10.1093/annonc/mdt320
2. De Kouchkovsky I, Abdul-Hay M. ‘Acute myeloid leukemia: A comprehensive review and 2016 update.’ Blood Cancer J. 2016;6(7):e441. doi:10.1038/bcj.2016.50
3. Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69-v82. doi:10.1093/annonc/mdw025
4. Kröger N. Approaches to relapse after allogeneic stem cell transplantation. Curr Opin Oncol. 2011;23(2):203-208. doi:10.1097/CCO.0b013e328342c6c8
5. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433-444. doi:10.1200/JCO.1997.15.2.433
6. Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2013;19(12):1713-1718. doi:10.1016/j.bbmt.2013.09.011
7. Porter DL, Alyea EP, Antin JH, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010;16(11):1467-1503. doi:10.1016/j.bbmt.2010.08.001
8. Weisdorf D. The role of second transplants for leukemia. Best Pract Res Clin Haematol. 2016;29(4):359-364. doi:10.1016/j.beha.2016.10.011
9. Eapen M, Giralt SA, Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34(8):721-727. doi:10.1038/sj.bmt.1704645
10. Döhner H, Estey EHE, Amadori S, et al. Diagnosis and management of AML in adults_Recommendations from European Leukemia Net 2010. Blood. 2010;115(3):453-474. doi:10.1182/blood-2009-07-235358.
11. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the Intensity of Conditioning Regimens: Working Definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633. doi:10.1016/j.bbmt.2009.07.004
12. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. doi:10.1016/j.bbmt.2014.12.001
13. Rihn C, Cilley J, Naik P, Pedicano AVJ, Mehta J. Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004;89(6):763-764. http://www.ncbi.nlm.nih.gov/pubmed/15194552.
14. Cerny J, Ramanathan M, Raffel G, Shanahan L, Kilmer E, Nath R. Outcomes of Second Allogeneic Stem Cell Transplantation: Single Center Analysis. Biol Blood Marrow Transplant. 2017;23(3):S264. doi:10.1016/j.bbmt.2016.12.162
15. Aljasem HA, Messner HA, Lipton JH, et al. Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience. Eur J Haematol. 2018;100(3):308-314. doi:10.1111/ejh.13015
16. Devillier R, Crocchiolo R, Etienne A, et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma. 2013;54(6):1228-1234. doi:10.3109/10428194.2012.741230
17. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015;21(3):454-459. doi:10.1016/j.bbmt.2014.11.007
18. Radich JP, Sanders JE, Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11(2):304-313. doi:10.1200/JCO.1993.11.2.304
19. Hartwig M, Ocheni S, Asenova S, et al. Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol. 2009;122(4):185-192. doi:10.1159/000253025
20. Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia consortium study. J Clin Oncol. 2010;28(4):648-654. doi:10.1200/JCO.2009.22.2950
21. Nguyen S, Béziat V, Norol F, et al. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation. Transfusion. 2011;51(8):1769-1778. doi:10.1111/j.1537-2995.2010.03058.x
22. Ueki T, Sumi M, Sato K, et al. Reduced-intensity cord blood transplantation without prior remission induction therapy induces durable remission in adult patients with relapsed acute leukemia after the first allogeneic transplantation. Eur J Haematol. 2011;86(3):268-271. doi:10.1111/j.1600-0609.2010.01555.x
23. Chueh HW, Lee SH, Sung KW, Yoo KH, Koo HH. Second allogeneic stem cell transplantation in hematologic malignancies: A single-center experience. J Pediatr Hematol Oncol. 2013;35(6):424-429. doi:10.1097/MPH.0b013e31829b7f58
24. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206. doi:10.1182/blood.V99.11.4200
25. Le RQ, Melenhorst JJ, Battiwalla M, et al. Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood. 2011;117(19):5250-5256. doi:10.1182/blood-2011-01-329706
26. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976-2980. doi:10.1182/blood-2004-04-1674
27. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19(16):3675-3684. doi:10.1200/JCO.2001.19.16.3675
28. Kishi K, Takahashi S, Gondo H, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: Results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant. 1997;19(5):461-466. doi:10.1038/sj.bmt.1700680
29. Byrne BJ, Horwitz M, Long GD, et al. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. Bone Marrow Transplant. 2008;41(1):39-43. doi:10.1038/sj.bmt.1705882
There is no Supplemental content for this article.

How to Cite This

BakırtaÅŸ, M., YiÄŸenoÄŸlu, T. N., BaÅŸcı, S., Uncu Ulu, B., Özcan, N., Ä°skender, D., … AltuntaÅŸ, F. (2020). Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience: SS. Jurnal Teknologi Laboratorium, 9(1), 87–96. https://doi.org/10.29238/teknolabjournal.v9i1.208

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].